Literature DB >> 22247338

Vitamin D insufficiency and deficiency among HIV-1-infected patients in a tropical setting.

Surasak Wiboonchutikul1, Somnuek Sungkanuparph, Sasisopin Kiertiburanakul, La-or Chailurkit, Angkana Charoenyingwattana, Wittaya Wangsomboonsiri, Wasun Chantratita, Boonsong Ongphiphadhanakul.   

Abstract

Vitamin D plays role in bone health and the regulation of the immune system. A cross-sectional study of serum 25-hydroxyvitamin D (25[OH]D) levels was conducted among HIV-1-infected Thai patients to determine the prevalence and associated factors of low vitamin D levels (25[OH]D <30 ng/mL) in tropical setting. 25-Hydroxyvitamin D was measured by liquid chromatography/tandem mass spectrometry. Of 178 patients, 58% received antiretroviral therapy at median (interquartile range [IQR]) duration of 7.4 (5.9-8.5) years. The prevalence of 25(OH)D deficiency (<20 ng/mL) and insufficiency (20-29.9 ng/mL) was 26.8% and 44.9%, respectively. Multivariate analysis showed that receiving efavirenz (EFV) was significantly associated with low vitamin D status (odds ratio = 3.60; 95% confidence interval, 1.06-12.15, P <.05). The mean (±standard deviation) level of 25(OH)D in patients receiving and not receiving EFV was 22.9 (6.6) and 28.6 (10.7) ng/mL, respectively, (P <.05). Low vitamin D status is common and needs to be assessed among HIV-infected patients including tropical residents especially when EFV is used.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22247338     DOI: 10.1177/1545109711432142

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  6 in total

1.  25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings.

Authors:  Fiona Havers; Laura Smeaton; Nikhil Gupte; Barbara Detrick; Robert C Bollinger; James Hakim; Nagalingeswaran Kumarasamy; Adriana Andrade; Parul Christian; Javier R Lama; Thomas B Campbell; Amita Gupta
Journal:  J Infect Dis       Date:  2014-05-05       Impact factor: 5.226

2.  Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings.

Authors:  Fiona P Havers; Barbara Detrick; Sandra W Cardoso; Sima Berendes; Javier R Lama; Patcharaphan Sugandhavesa; Noluthando H Mwelase; Thomas B Campbell; Amita Gupta
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

3.  Low bone mass in people living with HIV on long-term anti-retroviral therapy: A single center study in Uganda.

Authors:  Erisa Sabakaki Mwaka; Ian Guyton Munabi; Barbara Castelnuovo; Arvind Kaimal; William Kasozi; Andrew Kambugu; Philippa Musoke; Elly Katabira
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

4.  Prevalence and Predictors of Hypovitaminosis D in Ethiopian HIV-Infected Adults.

Authors:  Abebe Muche Belete; Alemu Adela Tefera; Mekasha Getnet; Adisu Asefa; Yared Asmare Aynalem; Wondimeneh Shibabaw Shiferaw
Journal:  HIV AIDS (Auckl)       Date:  2021-12-22

Review 5.  Bone health and HIV in resource-limited settings: a scoping review.

Authors:  Flavia Kiweewa Matovu; Lalita Wattanachanya; Mags Beksinska; John M Pettifor; Kiat Ruxrungtham
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

6.  Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.

Authors:  Patawee Boontanondha; Hataikarn Nimitphong; Suchawadee Musikarat; Aschara Ragkho; Sasisopin Kiertiburanakul
Journal:  Curr HIV Res       Date:  2020       Impact factor: 1.581

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.